Frontal lobe dementia, more formally called frontotemporal dementia (FTD), is a group of brain diseases that damage the frontal and temporal lobes, causing dramatic changes in personality, behavior, and language. Unlike Alzheimer’s disease, which typically starts with memory loss, FTD often strikes younger people and shows up first as shifts in how someone acts or speaks. It is the most common cause of dementia in people under 60, and average survival after symptoms begin is seven to 13 years.
The Three Main Subtypes
FTD falls into three clinical subtypes, each defined by which symptoms appear first and which part of the brain is most affected.
The behavioral variant is the most common form. It targets the frontal lobes, the part of the brain responsible for judgment, planning, and social behavior. People with this type develop striking personality changes: they may lose their sense of social boundaries, say inappropriate things, act impulsively, or become profoundly apathetic. The apathy is frequently mistaken for depression, but the two are distinct. A person with behavioral variant FTD often loses the ability to empathize or read other people’s emotions, which can be deeply disorienting for family members who feel like they’re living with a stranger.
The semantic variant affects the temporal lobes and gradually erodes a person’s knowledge of words and concepts. Someone might look at a common object, like a wrench, and have no idea what it is or what it’s called. They can still speak fluently and form grammatically correct sentences, but the words increasingly lose meaning. Over time, social and emotional difficulties develop as well.
The nonfluent variant disrupts the mechanics of speech itself. Sentences become short, stripped of grammar, and effortful. Speaking slows dramatically, and the person may stumble over sounds or drop small connecting words. Unlike the semantic variant, comprehension of individual words stays intact early on, but understanding complex sentences becomes difficult. Behavioral changes and problems with planning tend to develop later in the course of the disease.
The semantic and nonfluent variants are sometimes grouped together under the umbrella term “primary progressive aphasia,” since both primarily affect language rather than behavior.
How It Differs From Alzheimer’s Disease
FTD and Alzheimer’s are easy to confuse, especially in younger patients, but they damage different brain systems. Alzheimer’s typically begins with difficulty forming new memories, trouble navigating familiar places, and problems recalling recent conversations. FTD, by contrast, often leaves memory relatively intact in the early stages. What changes first is personality, social conduct, or language ability.
Research comparing FTD patients with Alzheimer’s patients at similar levels of overall impairment found that FTD patients performed significantly better on tasks involving drawing and calculations, abilities that are controlled by brain regions Alzheimer’s tends to damage early. These preserved skills, combined with personality changes and brain imaging patterns, help clinicians tell the two apart. The distinction matters because medications developed for Alzheimer’s do not help FTD and may actually worsen symptoms.
Who Gets It and Why
FTD can appear at almost any age in adulthood, but it most often surfaces between the late 40s and early 60s. The exact age depends partly on genetics. People carrying one particular gene mutation (in the MAPT gene, which affects a structural protein in brain cells) develop symptoms at an average age of about 50, while those with mutations in another gene (GRN, involved in cell growth and repair) average around 61. A third major genetic cause, a repeat expansion in the C9orf72 gene, produces symptoms at an average of about 58. In rare cases, onset has been documented as early as the late teens.
About 15% of familial FTD cases are caused by inherited mutations in one of these three genes. The remaining cases appear without a clear family pattern, though having a first-degree relative with any form of dementia modestly raises risk. For most people diagnosed with FTD, no single cause can be identified.
What Happens Inside the Brain
In a healthy brain, structural proteins keep neurons stable and functioning. In FTD, abnormal clumps of protein build up inside nerve cells in the frontal and temporal lobes, eventually killing them. The specific protein involved varies. About 40% of cases involve a protein called tau, which normally helps maintain the internal scaffolding of neurons. Over 50% involve a different protein called TDP-43, which plays a role in gene regulation. A smaller subset involves a third protein, FUS. Each of these creates distinct patterns of damage, but all converge on the same vulnerable brain regions.
This selective destruction explains the symptoms. The frontal lobes govern personality, impulse control, motivation, and social behavior. The temporal lobes house language comprehension and semantic knowledge. As neurons die in these areas, the functions they support deteriorate while other parts of the brain, particularly the regions handling vision and spatial awareness in the back of the brain, remain comparatively intact until much later.
How It Is Diagnosed
There is no single blood test or scan that definitively confirms FTD. Diagnosis relies on a combination of clinical evaluation, neuropsychological testing, and brain imaging. MRI scans typically reveal shrinkage of the frontal and temporal lobes, often more pronounced on the right side of the brain in the behavioral variant. The back of the brain usually looks normal by comparison, which helps distinguish FTD from other forms of dementia.
PET scans, which measure how actively different brain regions are using energy, can reveal reduced activity in the frontal and temporal areas even before visible shrinkage appears on MRI. Combining MRI with a follow-up PET scan yields a sensitivity of about 96%, meaning this pairing catches the vast majority of true cases. However, misdiagnosis remains a real problem. In about two-thirds of genetically confirmed FTD cases, MRI did not show the expected pattern of brain shrinkage, and roughly 40% of false positive PET results led to an initial misdiagnosis of a psychiatric disorder rather than dementia.
This overlap with psychiatric illness is one of the biggest diagnostic challenges. A middle-aged person who suddenly becomes apathetic, socially inappropriate, or emotionally flat is more likely to be evaluated for depression, bipolar disorder, or a personality change than for a neurodegenerative disease. The average delay between first symptoms and correct diagnosis can stretch for years.
Treatment and Daily Management
No medication can slow or stop the progression of FTD. Treatment focuses on managing the most disruptive symptoms and maintaining quality of life for as long as possible. Certain antidepressants, particularly SSRIs, can help reduce compulsive behaviors, irritability, and agitation. Trazodone, another type of antidepressant, is also used for behavioral symptoms. Antipsychotic medications are sometimes prescribed for severe agitation or aggression, but they carry serious risks in people with dementia, including a higher chance of death, and are used cautiously.
For the language variants, speech therapy can help people maintain communication skills longer and develop alternative strategies, like using pictures or gestures, as verbal ability declines. Occupational therapy and structured daily routines are often more helpful than medication for managing the behavioral variant. Simplifying the environment, reducing choices, and keeping a predictable schedule can lower agitation and confusion.
Caregiving for someone with FTD is unusually demanding because the person’s fundamental personality and social instincts change. Unlike Alzheimer’s, where a loved one may forget names but retain warmth and social graces, FTD can make someone seem indifferent, rude, or unrecognizable to the people closest to them. Support groups specifically for FTD caregivers can help families navigate the emotional weight of these changes and plan for increasing care needs as the disease progresses.